We are SK life science,a CNS-focused pharmaceutical company
Values define us
SK Life Science, Inc. (SKLSI) is driven by the needs of healthcare providers, patients, caregivers, and the CNS community—nothing else. From these needs our 6 core values were formed—they are more than words on a page; they are what you can expect from us.
We believe there is more to life when you connect health with happiness.
Be fully engaged
Appreciateand recognize people
Embody a pioneering spirit
Always do the right thing
We believe there is more to life when you connect health with happiness.
Tireless in our commitment to the CNS community
We are proud to be the first Korea-based company to successfully initiate an IND with the US FDA
We demonstrate our competitiveness and commitment to finding CNS therapies with a total of 16 active INDs with the US FDA in 2018
We currently have 8 compounds in the clinical development pipeline
SK life science: a history of discovery
Developing solutions that change what is possible in CNS treatment
Select a year
A global presence
SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and a part of SK Group—a large conglomerate global corporation
Commercialization of meaningful CNS products in the US
Our handpicked leadership team
We’ve been there, done that, and now we’re here to do things differently
We are ready, willing, and able to break conventions to address the unmet needs in CNS.
Jeong Woo Cho, PhD
Chief Executive Officer
Dr. Cho began his career at SK biopharmaceuticals in 2001, becoming COO/EVP and head of the drug development business. In that role, he was responsible for managing all activities associated with the clinical development programs for key CNS assets. Notably, Dr. Cho managed global project teams in the US, EU, and Asia, which generated 16 US INDs, 2 global phase 2b/3 programs in direct development, and 2 global NDAs and phase 3 programs in co-development stages.
In March 2017, Dr. Cho rose to become the CEO of SK biopharmaceuticals. A poised and strategic leader, Dr. Cho’s calm demeanor has been pivotal in creating a culture characterized by achievement and excellence across both SK biopharmaceuticals and SK life science.
Dr. Cho was educated at Texas A&M University where he received his PhD in biology in 1993.
Vice President &
Chief Commercial Officer
After 26 years at J&J, Sebby joined Cempra Pharmaceuticals as VP, Market Development, where he was responsible for all pre-commercial efforts, including KOL development and commercial advisory boards.
Sebby earned his BA in political science and public administration from St. John’s University, where he was captain of the baseball team and later was drafted by the Minnesota Twins. Sebby earned a master’s degree in organizational dynamics in 2001 from the University of Pennsylvania. “Off the field,” Sebby remains active with his wife of 31 years and his 2 sons on the slopes, at the lake, and on the links.
Hong-Wook Kim, PhD
Vice President &
Chief Operating Officer
In 2001, Dr. Kim joined SK and has held multiple leadership positions, including Head of Toxicology, Translational Research, Nonclinical Development and Clinical Safety. Dr. Kim also leads regulatory package preparations for numerous INDs, clinical trials, and an NDA. His experience encompasses a diverse spectrum of therapeutic areas that include epilepsy, depression, schizophrenia, cognition, ADHD, neuropathic pain, anxiety, Alzheimer’s, Parkinson’s, diabetes mellitus, chronic constipation, irritable bowel syndrome, and gastroparesis.
Dr. Kim attended Seoul National University, where he studied animal sciences and graduated with a BS in 1987 and an MS in 1989. He received his PhD in immunology, followed by postdoctoral training at Washington State University.
Marc Kamin, MD
Vice President &
Chief Medical Officer
During his career in the pharmaceutical industry, Dr. Kamin has designed and managed trials in many areas of neuroscience including migraine, eating disorders, bipolar disorder, alcohol addiction, acute and chronic pain, epilepsy, peripheral neuropathy, amyotrophic lateral sclerosis, and fibromyalgia. Throughout his career, he has been involved in the strategic aspects of drug development as well as medical marketing activities.
He has been the Chief Medical Officer at SK life science for 6 years and is responsible for providing medical and pharmacovigilance support for all human clinical trials conducted by SK life science. He is certified by the American Board of Psychiatry and Neurology.
Sales & Marketing
Jeff started his career at Ortho-McNeil, where he held a variety of sales and marketing positions during a 12-year tenure with a focus on CNS/epilepsy. For the 10 years that followed, Jeff served in leadership roles in sales and marketing and business development at Ethicon, Romark Laboratories, LC, Catalina USA, and Adheris Health. In April 2015, Jeff joined Cempra Pharmaceuticals as VP of Sales and Systems of Care to support their transition from a clinical stage to commercial stage pharmaceutical company. Jeff joined SK life science in the spring of 2017 to lead sales and marketing.
Jeff graduated magna cum laude in 1992 with a BS degree in marketing from St. John’s University, where he also played lacrosse. When he’s not attempting to drive positive change within the CNS field, Jeff is all about spending time with his wife, son, and daughter, especially during their annual ski vacation to Park City, Utah.
Robert is a strategic markets specialist with more than 25 years of results-driven experience. His tenacity and ability to strategize through multiple perspectives make him an unstoppable force in the areas of managed care and trade, and have allowed him to develop meaningful relationships and drive impactful strategies for US-based customers in commercial and government contracting, pricing, and trade channels.
Robert began his career in pharmaceuticals as a sales representative for Glaxo, then moved to the medical implantable space before 9 years at Johnson & Johnson, where he worked as both a manager and strategic markets director. Robert then moved on to Valeant Pharmaceuticals, where during his 9-year tenure he became Vice President of Strategic Markets and Vice President of Sales. Robert comes to SK life science from his most recent position with Cempra Pharmaceuticals, where he was recruited to execute commercial initiation as Vice President of Managed Care and Trade.
A graduate of the University of Florida’s Warrington College of Business, Robert earned his BS in Finance and Real Estate in 1988 and was a member of Pi Kappa Phi. Robert and his wife of 27 years enjoy spending their free time on the water boating on the east coast of Florida, traveling internationally, and visiting with their 2 adult children.
With nearly 2 decades of experience, Matthew is an expert at expanding revenue. During his time at Ortho-McNeil Pharmaceutical, Matthew worked with numerous marketing teams where he created strategic planning initiatives to maximize revenue across a number of sales channels. Matthew came to SK life science in April of 2017 after his most recent position as GM Sales and Promotional Effectiveness at IMS, where he worked with clients to build pharmaceutical sales teams and outsourced commercial operation solutions.
Matthew graduated from La Salle University’s School of Business Administration in 1991, where he earned his BS in marketing and management.
Chief Financial Officer
James earned a bachelor’s degree in Business Administration from Korea University. He then attended the S.C. Johnson Graduate School of Management at Cornell University from 2006-2008.
We are part of something bigger
SK life science is a subsidiary of SK biopharmaceuticals, focused on developing innovative, next-generation drugs. Both are a part of the global conglomerate SK Group, one of the largest companies you may have never heard of.
SK Group: key facts
Select a year for details
Become a global leader in CNS by unlocking the complex mysteries of the brain
Pushing innovation forward togetherWant to collaborate with us?
Because more can be done when people come together, we seek partnerships with universities, government organizations, and pharmaceutical and biotech companies across multiple therapeutic areas.
Select a disorder for details
References: 1. Lee Min-hyung. SK Group surges in market cap. Korea Times. August 14, 2017. http://www.koreatimes.co.kr/www/tech/2017/09/133_234676.html. Accessed October 8, 2018. 2.Data on file, SK life science. 3.Fortune Global 500 list for 2018. Fortune 500 Web site. http://fortune.com/global500/list/. Accessed October 8, 2018. 4.Zack MM, Kobau R. National and state estimates of the numbers of adults and children with active epilepsy—United States, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(31):821-825. 5.Centers for Disease Control and Prevention (CDC). At A Glance 2017: Epilepsy: one of the nation’s most common neurological conditions. www.cdc.gov/chronicdisease/resources/publications/aag/epilepsy.htm. Accessed October 8, 2018. 6.American Academy of Sleep Medicine. Rising prevalence of sleep apnea in U.S. threatens public health. https://aasm.org/rising-prevalence-of-sleep-apnea-in-u-s-threatens-public-health/. Published September 29, 2014. Accessed October 8, 2018. 7.Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. Am J Epidemiol. 2013;177(9):1006-1014. 8.Yawn BP, Wollan PC, Weingarten TN, et al. The prevalence of neuropathic pain: clinical evaluation compared with screening tools in a community population. Pain Med. 2009;10(3):586-593. 9.Schaefer C, Mann R, Sadosky A, et al. Burden of illness associated with peripheral and central neuropathic pain among adults seeking treatment in the United States: a patient-centered evaluation. Pain Med. 2014;15(12):2105-2119. 10.Alzheimer’s Association. 2017 Alzheimer’s disease facts and figures. Alzheimers Dement. 2017;13(4):325-373. 11.Kessler RC, Chiu WT, Demler O, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication [published correction appears in Arch Gen Psychiatry. 2005;62(7):709]. Arch Gen Psychiatry. 2005;62(6):617-627. 12.Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602. 13.Greenberg PE, Fournier A-A, Sisitsky T, Pike CT, Kessler RC. The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry. 2015;76(2):155-162. 14.Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002 [abstract]. J Clin Psychiatry. 2005;66(9):1122-1129. 15.National Institute of Mental Health. Any anxiety disorder among adults. https://www.nimh.nih.gov/health/statistics/prevalence/any-anxiety-disorder-among-adults.shtml. Accessed October 8, 2018. 16.Howden LM, Meyer JA. Age and sex composition: 2010. US Census Bureau Web site, 2010 Census Briefs. https://www.census.gov/prod/cen2010/briefs/c2010br-03.pdf. Accessed October 8, 2018.